XenaCare Announces Agreement to Sell Three of Its Clinical Products for Private Label to Renaissance Publishing

BOCA RATON, FL–(Marketwire – September 30, 2010) –  XenaCare Holdings, Inc. (OTCBB: XCHO) announced today that it has signed a private label marketing agreement with Renaissance Publishing LLC covering three of its clinical supplement products.

Under the terms of the agreement XenaCare will supply Renaissance with finished product for private label marketing in the United States with packaging and branding provided by Renaissance.

Commenting on the agreement, Frank Rizzo, President and CEO of XenaCare, states, “We are very pleased to be working with Renaissance for U.S. private label marketing of these proprietary clinical supplement products. They fit into Renaissance’s growing portfolio of anti-aging dietary supplements that promote increased health, well-being, and life expectancy and allow us to concentrate our efforts and resources on Cobroxin™. We believe that the Renaissance strategy of providing education about its products along with its direct response sales model will result in greater awareness and sales of these unique products and look forward to a successful relationship with Renaissance.”

XenaCare expects to strengthen its distribution matrix for future product introductions through a strategic relationship with Renaissance. Renaissance currently has an established 150,000 customer base and is a multimillion dollar company.

For further information:

http://www.XenaCareHoldings.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our anticipated future sales results for our products are forward looking statements. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s expectations. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov.